PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27325144-11 2018 In western blot analysis, montelukast was able to suppress LPS-induced MAPK-phospho-p38 and NF-kappaB-phospho-p65 expression. montelukast 26-37 nuclear factor kappa B subunit 1 Homo sapiens 92-101 27325144-12 2018 CONCLUSION: Montelukast suppressed LPS-induced M2-related cytokines and chemokines in alternatively activated macrophages, and the effects might be mediated through the MAPK-p38 and NF-kappaB-p65 pathways. montelukast 12-23 nuclear factor kappa B subunit 1 Homo sapiens 182-191 15984600-9 2005 CONCLUSIONS: These findings suggest that high doses of montelukast modulate the production of IL-6, TNF-alpha, and MCP-1 through the inhibition of NF-kappaB activation. montelukast 55-66 nuclear factor kappa B subunit 1 Homo sapiens 147-156 18325031-2 2008 In this study, we aimed to investigate the effect of montelukast on nuclear factor (NF)-kappaB-associated histone acetylation activity in phorbol myristate acetate (PMA)-differentiated U937 cells. montelukast 53-64 nuclear factor kappa B subunit 1 Homo sapiens 68-94 23954527-7 2013 Montelukast treatment prevented IL-8 release and heterologous beta2-adrenoceptor desensitization in human BSMC exposed to monocyte-derived MPs by blocking NF-kappaB nuclear translocation. montelukast 0-11 nuclear factor kappa B subunit 1 Homo sapiens 155-164 32949526-3 2020 An approved asthma drug, montelukast, has been found to modulate the activity of NF-kappaB, and result in a corresponding decrease in proinflammatory mediators. montelukast 25-36 nuclear factor kappa B subunit 1 Homo sapiens 81-90 15984600-2 2005 However, the action of montelukast in terms of nuclear factor KB (NF-kappaB) activation and the production of proinflammatory molecules is unknown. montelukast 23-34 nuclear factor kappa B subunit 1 Homo sapiens 62-64 15984600-2 2005 However, the action of montelukast in terms of nuclear factor KB (NF-kappaB) activation and the production of proinflammatory molecules is unknown. montelukast 23-34 nuclear factor kappa B subunit 1 Homo sapiens 66-75 15984600-4 2005 METHODS: We examined whether montelukast inhibits the activation of NF-kappaB, a transcription factor that regulates the expression of proinflammatory molecules. montelukast 29-40 nuclear factor kappa B subunit 1 Homo sapiens 68-77 15984600-6 2005 RESULTS: Flow cytometry demonstrated that montelukast inhibited NF-kappaB activation in THP-1 cells in a dose-related manner. montelukast 42-53 nuclear factor kappa B subunit 1 Homo sapiens 64-73 34004207-5 2021 Montelukast can ameliorate extra-pulmonary manifestations in Covid-19 either directly through blocking of Cys-LTRs in different organs or indirectly through inhibition of the NF-kappaB signaling pathway. montelukast 0-11 nuclear factor kappa B subunit 1 Homo sapiens 175-184 32949526-4 2020 Herein, we hypothesize that repurposing montelukast to suppress NF-kappaB activation will result in an attenuation of proinflammatory mediators and a decrease in cytokine production, thereby leading to a reduction in symptom severity and to improved clinical outcomes in patients with Coronavirus 2019 (COVID-19). montelukast 40-51 nuclear factor kappa B subunit 1 Homo sapiens 64-73